 Shares of DBV Technologies NASDAQ: DBVT were down a whopping 41.6 as of 11:41 a.m. EDT on Tuesday. The catalyst for this sell-off was the companys announcement that it has received a complete response letter from the Food and Drug Administration regarding its Biologics License Application BLA for Viaskin, a potential treatment for peanut allergy. DBV Technologies complied with this request, but it seems it wasnt enough to please the FDA. 